Ascension AL Grand Rounds Emerging Clinical Approaches in Allergy and Immunology (2023 - 2025)

---

ONLINEAllergy

Thursday, February 23, 2023, 6:00 AM - Sunday, February 23, 2025, 6:00 PM


AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance (1.00 hours), AAPA Credit(s) (1.00 hours), APA Credit(s) (1.00 hours), ANCC Contact Hour(s) (1.00 hours), ACPE Contact Hour(s) (1.00 hours)

This activity will review the understanding of allergic disorders with an emphasis on the translation of allergy knowledge to clinical practice.

Disclosures:
Faculty: Amy CaJacob, M.D.
* Has no relevant financial relationships with ACCME-defined commercial interests
* Will not be discussing the off-label or investigational use of products
* All Ascension planners and reviewers have no relevant financial relationships with ACCME-defined commercial interests.

Course Chair reviewed and found no Conflict of Interest

1. Recognize specific treatment modalities applicable to management of disease specific allergies and immunology
2. Describe the indications, appropriate patient selection and side effects of recent FDA approved medications in allergy, as well as emerging therapeutics for management of allergic disease
3. Review updates and clinical practice strategies in the areas of allergies and immunology

This activity was planned by and for the healthcare team, and learners will receive 1.00 IPCE credits for learning and change.

Ascension adheres to ACCME Criteria, Standards and Policies regarding industry support of CE/CME. Disclosure of faculty and their commercial relationships will be made prior to the activity.

Mitigation of Relevant Financial Relationships

Ascension adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Interest: No commercial interest was received for this CE/CME activity.